Create a free Clinical OMICs account to comment on articles, save favorites, create a profile, and more. By opting in below, you will also receive a free subscription to the digital version of Clinical OMICs Magazine and our eNewsletter.
Already have a Clinical OMICs account? Log In
Your first & last name
This field can be seen by: Everyone
This field can be seen by: Only Me
![CRISPR Therapeutics and Massachusetts General Hospital Cancer Center said they will use CRISPR/Cas9 gene editing to develop novel T cell therapies for blood and solid tumors. [Source: Feng Zhang and Steve Dixo]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1218-218x150.jpeg "Caribou Biosciences’ IPO Hauls in $304M to Fund Development of Gene-Edited Cell Therapies")
